Exco InTouch has announced that its novel eDiary technologies have been selected by Pfizer as part of the first ever Participatory Patient-Centered clinical trial. The pilot study will utilize Exco InTouch’s eDiary technologies to enable patients to participate regardless of location, age, or proximity to site. Focusing on new Research on Electronic Monitoring of OAB Treatment Experience Phase 4 for the treatment of overactive bladder, the study will mimic a previously completed trial in order to replicate the results and validate this novel approach.
In order to support the success of this patient-centered, field-based clinical research, Pfizer required a mobile technology platform offering an ease-of-use interface that provided accessibility particularly for older patients. With an estimated five billion cellphone users worldwide, cell phones make an ideal and accessible platform for patient engagement in clinical trials. As part of the new approach piloted by the REMOTE study, patients will be empowered to participate remotely in the screening process through trials via the internet, participate in trials that due to location may not have previously been possible, actively manage their own trial, and report results directly to a trial. As a result, researchers expect to save time and obtain more reliable, higher quality data through increased patient compliance and engagement, lower withdrawal rates and real-time data collection. The new approach will also eliminate the costs associated with the management and co-ordination of running multiple clinical sites.
Exco InTouch offers three validated ePRO solutions, spanning simple diaries to the most complex clinical assessments, all of which can be customized to meet the requirements of individual trials.These technologies have been developed with an intuitive design to provide easy navigation that enhances the user experience, while positively impacting on-going compliance from patients, regardless of their age and logistics.Where specific and targeted data collection is required, patients can complete diary questionnaires via a series of text messages sent to their own cellphone.If a response is not received by the patient within a certain timeframe, a text message reminder can be automatically sent in order to prompt a response. The ability to capture patient data in “real-time” means that investigator site staff can be alerted to abnormal patient data and react to ensure patient safety.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access